WO2024121861 - EGFR INHIBITOR FOR THE TREATMENT OF HEAD AND NECK CANCER
National phase entry is expected:
Publication Number
WO/2024/121861
Publication Date
13.06.2024
International Application No.
PCT/IN2023/051131
International Filing Date
05.12.2023
Title **
[English]
EGFR INHIBITOR FOR THE TREATMENT OF HEAD AND NECK CANCER
[French]
INHIBITEUR D'EGFR POUR TRAITER LE CANCER DE LA TÊTE ET DU COU
Applicants **
NATCO PHARMA LIMITED
Inventors
YADLA, Sheshu Babu
MYNENI, Praveen Chowdary
GOGULA, Venkata Ramana
NANNAPANENI, Venkaiah Chowdary
Priority Data
202241070753
08.12.2022
IN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
IP India
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2621 | |
| EPO | Filing, Examination, Granting | 20466 | |
| Japan | Filing, Examination, Granting | 2700 | |
| South Korea | Filing, Examination, Granting | 3225 | |
| USA | Filing, Examination, Granting | 8940 |
Total:
37,952
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The invention relates to the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck (preferably recurrent squamous cell carcinoma of the head and neck) with a compound which is (3-ethynyl-phenyl)-[7- methoxy-6-(3-morpholin-4-yl-propoxy)-quinazolin-4-yl]-amine (NRC-2694) or a pharmaceutically acceptable salt thereof. The invention also relates to the treatment of head and neck cancer with a compound which is (3-ethynyl-phenyl)-[7-methoxy- 6-(3-morpholin-4-yl-propoxy)-quinazolin-4-yl]-amine (NRC-2694) or a pharmaceutically acceptable salt thereof, wherein the treating the head and neck cancer comprises reducing the size of one or more tumours associated with the head and neck cancer.[French]
L'invention concerne le traitement du carcinome à cellules squameuses récurrent et/ou métastatique de la tête et du cou (de préférence le carcinome à cellules squameuses récurrent de la tête et du cou) avec un composé qui est la (3-éthynyl-phényl)-[7-méthoxy-6-(3-morpholin-4-yl-propoxy)-quinazolin-4-yl]-amine (NRC-2694) ou un sel pharmaceutiquement acceptable de celle-ci. L'invention concerne également le traitement du cancer de la tête et du cou avec un composé qui est la (3-éthynyl-phényl)-[7-méthoxy-6-(3-morpholin-4-yl-propoxy)-quinazolin-4-yl]-amine (NRC-2694) ou un sel pharmaceutiquement acceptable de celle-ci, le traitement du cancer de la tête et du cou comprenant la réduction de la taille d'une ou de plusieurs tumeurs associées au cancer de la tête et du cou.